Latest CD20 Stories
- Anthera to receive up to $48,000,000 plus future product margin on commercial supply HAYWARD, Calif., Dec. 15, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
Health Canada approves GAZYVA((TM)) (obinutuzumab), a medicine that harnesses the body's immune system to kill cancer cells, for patients with chronic lymphocytic leukemia (or CLL)
Investigators' Oral and Poster Presentations Highlight Canine Lymphoma Antibody Programs KANSAS CITY, Kan., Oct.
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy.
LONDON, April 17, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S.
DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/7dhkqb/investigation) has announced the addition of the "Investigation
Kanti Rai, MD, and Jacqueline Barrientos, MD, comment on study of new leukemia therapy. Lake Success, NY (PRWEB) March 20, 2014 Two
Antibodies against the B cell surface protein CD20 have been used successfully to treat B cell-mediated autoimmune diseases and lymphomas.
- A volcanic mudflow.